共 50 条
- [41] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)BMC Cancer, 14Jisun KimWoosung LimEun-Kyu KimMin-Kyoon KimNam-Sun PaikSang-Seol JeongJung-han YoonChan Heun ParkSei Hyun AhnLee Su KimSehwan HanSeok Jin NamHan-Sung KangSeung Il KimYoung Bum YooJoon JeongTae Hyun KimTaewoo KangSung-Won KimYongsik JungJeong Eon LeeKu Sang KimJong-Han YuByung Joo ChaeSo-Youn JungEunyoung KangSu Yun ChoiHyeong-Gon MoonDong-Young NohWonshik Han
- [42] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)BMC CANCER, 2014, 14Kim, JisunLim, WoosungKim, Eun-KyuKim, Min-KyoonPaik, Nam-SunJeong, Sang-SeolYoon, Jung-hanPark, Chan HeunAhn, Sei HyunKim, Lee SuHan, SehwanNam, Seok JinKang, Han-SungKim, Seung IlYoo, Young BumJeong, JoonKim, Tae HyunKang, TaewooKim, Sung-WonJung, YongsikLee, Jeong EonKim, Ku SangYu, Jong-HanChae, Byung JooJung, So-YounKang, EunyoungChoi, Su YunMoon, Hyeong-GonNoh, Dong-YoungHan, Wonshik
- [43] A phase II trial with safety run-in of neoadjuvant therapy with an aromatase inhibitor in combination with durvalumab (MEDI4736) in postmenopausal patients with hormone-receptor-positive (HR plus ) breast cancerCANCER RESEARCH, 2021, 81 (04)Khong, Hung T.Goodridge, Dawn N.Khakpour, NazaninLee, M. CatherineLaronga, ChristineArmaghani, Avan J.Soyano-Muller, Aixa E.Han, HyoSoliman, HatemCosta, RicardoLoftus, LorettaHoover, Susan J.Kiluk, John V.Jameel, ZenaCzerniecki, Brian J.
- [44] Efficacy of fulvestrant in treating postmenopausal patients with estrogen receptor-positive metastatic breast cancer and prognostic analysisJOURNAL OF BUON, 2021, 26 (01): : 189 - 195Li, TaoJiao, Lianghe
- [45] Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER plus ) breast cancer: Relevance to palliative treatmentJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Symmans, William FraserAndreopoulou, EleniBooser, Daniel J.Hatzis, ChristosWallace, Michael J.Zhang, YaGong, YunIgnatiadis, MichailSotiriou, ChristosAndre, FabricePeintinger, FlorentinaRegitnig, PeterMarth, ChristianDesmedt, ChristineLoi, ShereneMoulder, Stacy L.Hortobagyi, Gabriel N.Pusztai, LajosValero, Vicente
- [46] Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast CancerBREAST JOURNAL, 2017, 23 (03): : 376 - 376Altundag, Kadri
- [47] CLINICAL EFFICACY OF LH-RH ANALOGUE PLUS AROMATASE INHIBITOR IN PREMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER: A SINGLE-INSTITUTION RETROSPECTIVE STUDYBREAST, 2015, 24 : S41 - S41Utsumi, ToshiakiKobayashi, NaomiHikichi, MasahiroUshimado, KaoriRi, Yuki
- [48] Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.CANCER RESEARCH, 2011, 71Wright, G. L.Blum, J.Krekow, L. K.McIntyre, K. J.Wilks, S. T.Rabe, A. C.Vukelja, S. J.Andersen, J. C.Wang, Y.Asmar, L.O'Shaughnessy, J.
- [49] Factors influencing the uptake of [F-18]fluoroestradiol (FES) in patients with estrogen receptor positive (ER plus ) breast cancerJOURNAL OF NUCLEAR MEDICINE, 2010, 51Peterson, LanellKurland, BrendaLink, JeanneSchubert, ErinStekhova, SvetlanaLinden, HannahChai, XiaoyuMankoff, David
- [50] COST EFFECTIVENESS ANALYSIS OF EVEROLIMUS plus EXEMESTANE FOR PATIENTS WITH ADVANCED BREAST CANCER WITH POSITIVE ESTROGEN RECEPTOR (ER +), HER2-, REFRACTORY TO NON-STEROIDAL AROMATASE INHIBITORS (NSAIS) IN CHILEVALUE IN HEALTH, 2014, 17 (07) : A634 - A634Ratto, B.Ulloa, Torres R.Veneros, Cerda H.Anaya, P.